Effectiveness of Ursodeoxycholic Acid for Liver Diseases

Introduction to UDCA Treatment

• The European Association for the Study of the Liver recommends UDCA at doses of 13-15 mg/kg/day as the established treatment of choice for primary biliary cirrhosis (PBC) based on multiple placebo-controlled trials and long-term case-control studies 1
• UDCA significantly decreases serum bilirubin, alkaline phosphatase, cholesterol, and immunoglobulin M levels in PBC patients compared to placebo 1, 2
• Long-term UDCA treatment delays histological progression of PBC when started at an early stage of the disease 1
• UDCA treatment is associated with a significant reduction in the likelihood of liver transplantation or death in patients with moderate to severe PBC 1, 2

Treatment Recommendations for Specific Liver Diseases

• For PBC: UDCA at 13-15 mg/kg/day is the recommended first-line therapy 1, 2
• For PSC: The American Association for the Study of Liver Diseases does not support routine use of UDCA 3
• The British Society of Gastroenterology recommends against routine use of UDCA for newly diagnosed PSC due to limited efficacy and potential harm at high doses 4

Monitoring and Follow-up for UDCA Treatment

• Regular monitoring of liver biochemistry is essential to assess treatment response 1
• AMA-positive individuals with normal liver tests should undergo annual reassessment of biochemical markers of cholestasis 1
• Liver biopsy may be needed for diagnosis in the absence of PBC-specific antibodies 1
• UDCA has not demonstrated significant effects on symptoms like fatigue or pruritus in PBC 1, 2

Dosis de Ácido Ursodeoxicólico para Colestasis

Dosificación según tipo de colestasis

• La dosis recomendada de ácido ursodeoxicólico para cirrosis biliar primaria es 13-15 mg/kg/día, considerada la terapia de primera línea 5
• La dosis recomendada para colangitis esclerosante primaria es 15-20 mg/kg/día, aunque la evidencia de beneficio es limitada 6
• La dosis inicial recomendada para colestasis intrahepática del embarazo es 10-15 mg/kg/día, dividida en 2-3 dosis diarias 7

Consideraciones importantes

Monitorización del tratamiento

• En colestasis intrahepática del embarazo, se recomienda medir los ácidos biliares séricos al menos semanalmente a partir de las 32 semanas de gestación 8
• La respuesta bioquímica debe evaluarse después de 1 año de terapia con AUDC para identificar pacientes en riesgo de enfermedad progresiva 5

Efectos secundarios

• El AUDC generalmente es bien tolerado, aunque pueden presentarse náuseas y mareos leves en hasta 25% de los pacientes 7

Precauciones

• Durante el embarazo, el AUDC a dosis medias se considera seguro y debe continuarse en pacientes con CBP y CEP 6

Ursodeoxycholic Acid (UDCA) Therapy

Controversial Indications

• The American Association for the Study of Liver Diseases recommends against the use of UDCA as medical therapy for adult patients with primary sclerosing cholangitis (PSC) 9, 10
• Higher doses of UDCA (20-25 mg/kg/day) have shown some improvements in liver fibrosis histology and cholangiographic appearances in PSC patients, but clinical outcomes remain uncertain 11

Safety and Pregnancy

• UDCA is considered safe during pregnancy and breastfeeding, particularly for women with primary biliary cirrhosis (PBC) and PSC who require continued treatment 12

UDCA Dosage and Frequency

Introduction to UDCA Dosage

• The American College of Obstetricians and Gynecologists recommends a dosage of 10-15 mg/kg/day divided into 2-3 doses for intrahepatic cholestasis of pregnancy (ICP) 13
• The European Association for the Study of the Liver suggests a dosage of 15-20 mg/kg/day for primary sclerosing cholangitis (PSC), though routine use is not recommended due to limited efficacy and potential harm at higher doses 14

Primary Biliary Cirrhosis (PBC) and Intrahepatic Cholestasis of Pregnancy (ICP)

• UDCA is recommended as the first-line agent for treating maternal symptoms of ICP, with proven efficacy in reducing pruritus and improving laboratory abnormalities without known adverse fetal effects 13
• A decrease in pruritus typically occurs within 1-2 weeks, and biochemical improvement is usually seen within 3-4 weeks in patients with ICP 13
• If pruritus is not relieved, the dose can be titrated to a maximum of 21 mg/kg/day in patients with ICP 13

Primary Sclerosing Cholangitis (PSC)

• UDCA at doses of 15-20 mg/kg/day can be given for PSC since it may improve serum liver tests and surrogate markers of prognosis, though available data does not support a firm recommendation 14
• UDCA at doses of 28-30 mg/kg/day should NOT be given in PSC due to enhanced risk of reaching primary endpoints including liver transplantation and development of varices in more advanced disease 14

ABCB4 Deficiency and SC-CIP

• Low-to-medium-dose UDCA (10-15 mg/kg/day) can be given in patients with ABCB4 deficiency and SC-CIP, though evidence is limited, providing anticholestatic and anti-inflammatory effects while stimulating biliary bicarbonate secretion 15

Critical Safety Warning

• The American Association for the Study of Liver Diseases and the British Society of Gastroenterology do not support routine use of UDCA for PSC due to limited efficacy and potential harm at high doses, as documented in the Journal of Hepatology 14

Duration and Monitoring of Ursodeoxycholic Acid Treatment

When to Discontinue Treatment

• In patients with hepatic decompensation, particularly those with advanced disease, discontinuation of ursodeoxycholic acid may be necessary 16

Ursodeoxycholic Acid Treatment Guidelines

Introduction to UDCA Treatment

• The European Association for the Study of the Liver recommends that UDCA should be given lifelong after liver transplantation to all primary biliary cholangitis patients to prevent recurrence 17

Optimal Dosing and Administration

• The American Association for the Study of Liver Diseases suggests that for primary biliary cholangitis, UDCA should be administered at 13-15 mg/kg/day in two divided doses, with lifelong therapy at 10-15 mg/kg/day for post-liver transplant patients 17

Post-Liver Transplantation Care

• The European Society of Gastrointestinal Endoscopy recommends lifelong UDCA therapy at 10-15 mg/kg/day for post-liver transplant primary biliary cholangitis patients 17

Safety and Contraindications of Ursodeoxycholic Acid

Adverse Effects

Overall Safety Profile

Contraindications